Cargando…

C3d Elicits Neutrophil Degranulation and Decreases Endothelial Cell Migration, with Implications for Patients with Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin (AAT) deficiency (AATD) is characterized by increased risk for emphysema, chronic obstructive pulmonary disease (COPD), vasculitis, and wound-healing impairment. Neutrophils play a central role in the pathogenesis of AATD. Dysregulated complement activation in AATD results in inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fee, Laura T., Gogoi, Debananda, O’Brien, Michael E., McHugh, Emer, Casey, Michelle, Gough, Ciara, Murphy, Mark, Hopkins, Ann M., Carroll, Tomás P., McElvaney, Noel G., Reeves, Emer P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698851/ https://www.ncbi.nlm.nih.gov/pubmed/34944741 http://dx.doi.org/10.3390/biomedicines9121925

Ejemplares similares

A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application
por: O’Brien, Michael E., et al.
Publicado: (2022)

The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals
por: Dunlea, Danielle M, et al.
Publicado: (2018)

Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency
por: O'Brien, Michael E, et al.
Publicado: (2020)

Targeting of Glycosaminoglycans in Genetic and Inflammatory Airway Disease
por: Caird, Robin, et al.
Publicado: (2022)

Dysregulated neutrophil function in individuals with alpha-1 antitrypsin deficiency caused by modified membrane cholesterol content.
por: Jundi, Bakr, et al.
Publicado: (2015)

Altered Degranulation and pH of Neutrophil Phagosomes Impacts Antimicrobial Efficiency in Cystic Fibrosis
por: Hayes, Elaine, et al.
Publicado: (2020)

Alpha-1 Antitrypsin Augmentation Inhibits Proteolysis of Neutrophil Membrane Voltage-Gated Proton Channel-1 in Alpha-1 Deficient Individuals
por: Hawkins, Padraig, et al.
Publicado: (2021)

The prevalence of liver abnormalities in individuals with ZZ Alpha-1 Antitrypsin deficiency
por: McElvaney, OF, et al.
Publicado: (2015)

The role of TIM-containing molecules in airway disease and their potential as therapeutic targets
por: Vega-Carrascal, Isabel, et al.
Publicado: (2012)

Diagnosing α(1)-antitrypsin deficiency: how to improve the current algorithm
por: McElvaney, Noel G.
Publicado: (2015)

Hypertonic Saline in Treatment of Pulmonary Disease in Cystic Fibrosis
por: Reeves, Emer P., et al.
Publicado: (2012)

Targeting IgG Autoantibodies for Improved Cytotoxicity of Bactericidal Permeability Increasing Protein in Cystic Fibrosis
por: McQuillan, Karen, et al.
Publicado: (2020)

The Involvement of Glycosaminoglycans in Airway Disease Associated with Cystic Fibrosis
por: Reeves, Emer P., et al.
Publicado: (2011)

The prevalence of alpha-1 antitrypsin deficiency in Ireland
por: Carroll, Tomás P, et al.
Publicado: (2011)

In vitro and in vivo modulation of NADPH oxidase activity and reactive oxygen species production in human neutrophils by α(1)-antitrypsin
por: Hawkins, Padraig, et al.
Publicado: (2021)

Is There a Therapeutic Role for Selenium in Alpha-1 Antitrypsin Deficiency?
por: Greene, Catherine M., et al.
Publicado: (2013)

Alpha-1 antitrypsin regulates neutrophil reactive oxygen species production via inhibition of key players of the respiratory burst oxidase system
por: Alfawaz, Bader, et al.
Publicado: (2013)

Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
por: McLean, Caitriona, et al.
Publicado: (2009)

Alpha-1 antitrypsin for cystic fibrosis complicated by severe cytokinemic COVID-19
por: McElvaney, Oliver J, et al.
Publicado: (2021)

Animal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and Divergences
por: Lavelle, Gillian M., et al.
Publicado: (2016)

Physical Activity, Exercise Capacity and Sedentary Behavior in People with Alpha-1 Antitrypsin Deficiency: A Scoping Review
por: O’Shea, Orlagh, et al.
Publicado: (2023)

Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications
por: Chapman, Kenneth R, et al.
Publicado: (2018)

5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency
por: Mueller, Christian, et al.
Publicado: (2017)

Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes
por: Chotirmall, Sanjay H, et al.
Publicado: (2015)

Airway inflammatory markers in individuals with cystic fibrosis and non-cystic fibrosis bronchiectasis
por: Bergin, David A, et al.
Publicado: (2013)

Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme
por: Greulich, Timm, et al.
Publicado: (2018)

A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19
por: McElvaney, Oliver J., et al.
Publicado: (2022)

Neutrophil Membrane Cholesterol Content is a Key Factor in Cystic Fibrosis Lung Disease
por: White, Michelle M., et al.
Publicado: (2017)

Alpha-1 antitrypsin augmentation therapy decreases miR-199a-5p, miR-598 and miR-320a expression in monocytes via inhibition of NFκB
por: Hassan, Tidi, et al.
Publicado: (2017)

Clinical considerations in individuals with α(1)-antitrypsin PI*SZ genotype
por: McElvaney, Gerard N., et al.
Publicado: (2020)

Intracellular Secretory Leukoprotease Inhibitor Modulates Inositol 1,4,5-Triphosphate Generation and Exerts an Anti-Inflammatory Effect on Neutrophils of Individuals with Cystic Fibrosis and Chronic Obstructive Pulmonary Disease
por: Reeves, Emer P., et al.
Publicado: (2013)

Interleukin-6: obstacles to targeting a complex cytokine in critical illness
por: McElvaney, Oliver J, et al.
Publicado: (2021)

The effect of exacerbations on lung density in α(1)-antitrypsin deficiency
por: Strange, Charlie, et al.
Publicado: (2023)

Reply to Blot et al. and to Inoue et al.
por: McElvaney, Oliver J., et al.
Publicado: (2021)

Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications
por: McElvaney, Oisin F., et al.
Publicado: (2022)

The importance of CFTR expression for neutrophil function in patients with Cystic Fibrosis
por: Jundi, B, et al.
Publicado: (2015)

Secretory leucoprotease inhibitor binds to NF-κB binding sites in monocytes and inhibits p65 binding
por: Taggart, Clifford C., et al.
Publicado: (2005)

Diagnosis and management of α(1)-antitrypsin deficiency in Europe: an expert survey
por: Horváth, Ildikó, et al.
Publicado: (2019)

Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency
por: Tortorici, Michael A., et al.
Publicado: (2017)

Phospholipid transfer protein and alpha-1 antitrypsin regulate Hck kinase activity during neutrophil degranulation
por: Ochieng, Pius, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0avv09danaqloj3fpd77630vnm